Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

July 27, 2004; 63 (2) Clinical/Scientific Notes

The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands

P. W. Wirtz, J. G. van Dijk, P. A. van Doorn, B. G.M. van Engelen, A. J. van der Kooi, J. B. Kuks, A. Twijnstra, M. de Visser, L. H. Visser, J. H. Wokke, A. R. Wintzen, J. J. Verschuuren
First published July 26, 2004, DOI: https://doi.org/10.1212/01.WNL.0000130254.27019.14
P. W. Wirtz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. G. van Dijk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. A. van Doorn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. G.M. van Engelen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. J. van der Kooi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. B. Kuks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Twijnstra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. de Visser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. H. Visser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. H. Wokke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. R. Wintzen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. J. Verschuuren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands
P. W. Wirtz, J. G. van Dijk, P. A. van Doorn, B. G.M. van Engelen, A. J. van der Kooi, J. B. Kuks, A. Twijnstra, M. de Visser, L. H. Visser, J. H. Wokke, A. R. Wintzen, J. J. Verschuuren
Neurology Jul 2004, 63 (2) 397-398; DOI: 10.1212/01.WNL.0000130254.27019.14

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
408

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

The Lambert-Eaton myasthenic syndrome (LEMS) is presumed to be rare, but epidemiologic studies in large circumscribed populations have not been performed. Small cell lung carcinoma (SCLC) is said to be present in about 50% of LEMS patients, but this frequency might be subject to bias, as estimates were based on retrospective data from large specialized centers.1–4⇓⇓⇓ We established the prevalence and incidence of LEMS and the frequency of underlying SCLC in the Netherlands.

Patients and methods.

The study period ran from July 1, 1998, to July 1, 2003, and concerned the entire Netherlands, with 16,221,695 inhabitants by July 1, 2003. All eight university hospitals and eight large neurologic centers participated in this study. Patients were identified through standard hospital databases using codes 358.0 and 358.1 of the International Classification of Diseases, 9th revision, or using the Dutch neurologic coding system according to Kortbeek, or using the neuromuscular databases in the university hospitals. To overcome a possible referral bias we sent a letter to all neurologists in the Netherlands in a search for other LEMS patients, backed by additional attention to the aims of this study by publications in Dutch medical journals and presentations to neurologists and pulmonologists. Case finding was started on July 1, 1998.

After obtaining informed consent, one examiner (P.W.W.) interviewed and examined all patients. If this was not possible, clinical records were studied. We recorded demographic and clinical features, including date of onset of LEMS, date of first visit to a neurologist, signs and symptoms of LEMS, date of diagnosis of LEMS and of SCLC, results of diagnostic tests, any incorrect diagnoses, and date of death. EMG reports were evaluated, and an EMG with repetitive nerve stimulation was repeated whenever possible. In all but one patient, serum was available for testing of antibodies against P/Q-type voltage gated calcium channels. Patients with a diagnosis of LEMS were included if they had an abnormal EMG or P/Q-type voltage gated calcium channel antibodies, in addition to variable muscle weakness. Results of repetitive nerve stimulation were considered compatible with LEMS when an increment of more than 100% was obtained after either maximal voluntary muscle contraction or high frequency stimulation.

We calculated 95% CI assuming a Poisson distribution. Population figures for the Netherlands were based on data provided by the Statistics Netherlands, a department of the Ministry of Economic Affairs.5 We tested differences in clinical features between groups with and without SCLC with the Mann-Whitney test or Fisher’s exact test when appropriate, and considered a p value of < 0.05 significant.

Results.

Fifty-two patients were available for study (table), after excluding five cases in which diagnostic criteria were not met. We examined 36 patients at the Leiden University Medical Center and eight in their local hospital, leaving eight patients for whom only clinical records were reviewed. In patients with SCLC, the median interval between onset of LEMS-related symptoms and diagnosis of SCLC was 4.5 months (ranging from 41 months before to 4 months after SCLC diagnosis). Three patients without SCLC had a follow-up of less than 2 years after onset of LEMS. Eleven patients died before July 2003 (nine with SCLC). On July 1, 2003, 41 patients survived (eight with SCLC), resulting in a prevalence estimate of 2.5 per million inhabitants, which had almost doubled during our study period (1.3 × 10−6 by July 1, 1998). Dividing the Netherlands into four major regions as defined by the Statistics Netherlands, prevalence in the north was 3.0, the west 2.8, the east 1.8, and the south 2.8 per million inhabitants (differences not significant). Thirty-two new cases, including 15 with SCLC (47%), were ascertained during the 5-year study period (5 to 8 per year).

View this table:
  • View inline
  • View popup

Table Patient characteristics, prevalence, and incidence of the Lambert-Eaton myasthenic syndrome (LEMS)

The median duration of disease until diagnosis of LEMS was higher in LEMS patients without SCLC than in those with SCLC (p < 0.001, see the table). Thirty patients (58%) had received an incorrect diagnosis before LEMS was established. This most often concerned myasthenia gravis (n = 17), polyneuropathy (n = 6), and myopathy (n = 3). In 9 patients (18%) a muscle biopsy had been performed.

Discussion.

The incidence of SCLC associated LEMS equaled that of LEMS without SCLC, whereas the prevalence was lower, as a result of poor survival from SCLC. The frequency of 47% of SCLC in newly diagnosed LEMS patients is in line with previous reports (42 to 61%).1–4⇓⇓⇓ SCLC is generally evident within the first 2 years after onset of LEMS.2,3⇓ As three of our patients without SCLC had a follow-up of less than 2 years, the frequency of underlying SCLC could be slightly higher. The duration of disease until LEMS diagnosis was significantly shorter in patients who had an underlying SCLC. The presence of SCLC could not explain this difference, because in all but one patient LEMS diagnosis preceded diagnosis of SCLC. Possibly, LEMS with underlying SCLC has a more progressive course, which could shorten both patient and doctor delay.

Epidemiologic data on LEMS are scarce. A Danish study on myasthenia gravis reported a low annual incidence of LEMS of 0.17 per million, but the study was not primarily aimed at LEMS and the prevalence was not calculated.6 The incidence and prevalence in the present study were similar to those in our regional study in the province of South Holland, comprising 1.7 million inhabitants,7 suggesting that the methods of case collection were equally appropriate nationwide, as is further supported by the comparable prevalences in four regions of the Netherlands. The participation of all university hospitals, together with the generally well-organized registration systems in Dutch hospitals, maximized case ascertainment.

However, the considerable doctor delay and incorrect diagnosis indicate that LEMS may be underdiagnosed. Furthermore, prevalence during our 5-year study period almost doubled, which suggests underdiagnosis at least before the start of our case collection. Better knowledge of the clinical features of LEMS and easier availability of the antibody assay in the Netherlands in the last years may have increased the recognition of LEMS.

Acknowledgments

P.W.W. was supported by a grant of the Prinses Beatrix Fonds.

  • Received January 23, 2004.
  • Accepted March 8, 2004.

References

  1. ↵
    Elmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc. 1968; 43: 689–713.
    OpenUrlPubMed
  2. ↵
    O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988; 111: 577–596.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000; 54: 2176–2178.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology. 2002; 59: 1773–1775.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Statistics Netherlands. Statline. Available at: http://statline.cbs.nl/StatWeb. Accessed November 19, 2003.
  6. ↵
    Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol. 1991; 48: 733–739.
    OpenUrlCrossRefPubMed
  7. ↵
    Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol. 2003; 250: 698–701.
    OpenUrlCrossRefPubMed
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Patients and methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All epidemiology
  • Myasthenia
  • Prevalence studies
  • Incidence studies

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Resident and Fellow Section
    Child Neurology: Diagnosis of Lambert-Eaton myasthenic syndrome in children
    Bethanie Morgan-Followell, Emily de los Reyes et al.
    Neurology, May 20, 2013
  • Article
    Long‐term follow‐up, quality of life, and survival of patients with Lambert‐Eaton myasthenic syndrome
    Alexander F. Lipka, Marion I. Boldingh, Erik W. van Zwet et al.
    Neurology, December 12, 2019
  • Article
    Congenital myasthenic syndromes in adult neurology clinic
    A long road to diagnosis and therapy
    Justin C. Kao, Margherita Milone, Duygu Selcen et al.
    Neurology, October 05, 2018
  • Brief Communications
    Neuroendocrine lung tumors and disorders of the neuromuscular junction
    Ted M. Burns, Vern C. Juel, Donald B. Sanders et al.
    Neurology, April 01, 1999
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise